Cargando…

The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer

Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Arriaga-Canon, Cristian, Contreras-Espinosa, Laura, Aguilar-Villanueva, Sergio, Bargalló-Rocha, Enrique, García-Gordillo, José Antonio, Cabrera-Galeana, Paula, Castro-Hernández, Clementina, Jiménez-Trejo, Francisco, Herrera, L. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138835/
https://www.ncbi.nlm.nih.gov/pubmed/37108589
http://dx.doi.org/10.3390/ijms24087426
_version_ 1785032800943996928
author Arriaga-Canon, Cristian
Contreras-Espinosa, Laura
Aguilar-Villanueva, Sergio
Bargalló-Rocha, Enrique
García-Gordillo, José Antonio
Cabrera-Galeana, Paula
Castro-Hernández, Clementina
Jiménez-Trejo, Francisco
Herrera, L. A.
author_facet Arriaga-Canon, Cristian
Contreras-Espinosa, Laura
Aguilar-Villanueva, Sergio
Bargalló-Rocha, Enrique
García-Gordillo, José Antonio
Cabrera-Galeana, Paula
Castro-Hernández, Clementina
Jiménez-Trejo, Francisco
Herrera, L. A.
author_sort Arriaga-Canon, Cristian
collection PubMed
description Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life.
format Online
Article
Text
id pubmed-10138835
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101388352023-04-28 The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer Arriaga-Canon, Cristian Contreras-Espinosa, Laura Aguilar-Villanueva, Sergio Bargalló-Rocha, Enrique García-Gordillo, José Antonio Cabrera-Galeana, Paula Castro-Hernández, Clementina Jiménez-Trejo, Francisco Herrera, L. A. Int J Mol Sci Review Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life. MDPI 2023-04-18 /pmc/articles/PMC10138835/ /pubmed/37108589 http://dx.doi.org/10.3390/ijms24087426 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Arriaga-Canon, Cristian
Contreras-Espinosa, Laura
Aguilar-Villanueva, Sergio
Bargalló-Rocha, Enrique
García-Gordillo, José Antonio
Cabrera-Galeana, Paula
Castro-Hernández, Clementina
Jiménez-Trejo, Francisco
Herrera, L. A.
The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
title The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
title_full The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
title_fullStr The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
title_full_unstemmed The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
title_short The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
title_sort clinical utility of lncrnas and their application as molecular biomarkers in breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138835/
https://www.ncbi.nlm.nih.gov/pubmed/37108589
http://dx.doi.org/10.3390/ijms24087426
work_keys_str_mv AT arriagacanoncristian theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT contrerasespinosalaura theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT aguilarvillanuevasergio theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT bargallorochaenrique theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT garciagordillojoseantonio theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT cabreragaleanapaula theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT castrohernandezclementina theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT jimeneztrejofrancisco theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT herrerala theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT arriagacanoncristian clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT contrerasespinosalaura clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT aguilarvillanuevasergio clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT bargallorochaenrique clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT garciagordillojoseantonio clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT cabreragaleanapaula clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT castrohernandezclementina clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT jimeneztrejofrancisco clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer
AT herrerala clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer